The Absorb GT1 bioresorbable vascular scaffold (BVS, Abbott Vascular) will no longer be widely available in Europe as of May 31, 2017, with the company restricting use of the device to centers ...

WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...

Abbott said it will monitor bioabsorbable stent implantations in Europe, following a high rate of heart attacks in European Absorb GT1 patients, plus a separate FDA safety alert regarding adverse ...

Abbott Laboratories, one of the biggest makers of coronary stents in the world, is halting global sales of a fully absorbable stent that was once hailed as the next big breakthrough in medical devices ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio At 2 years after implantation, a fully ...

SAN FRANCISCO, CA — A head-to-head comparison of the everolimus-eluting stent with a bioresorbable scaffold (Absorb, Abbott Vascular) against a conventional everolimus-eluting cobalt-chromium stent ...

In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the ...

CALGARY, Alberta--(BUSINESS WIRE)--Absorb Software Inc., a leading provider of cloud-based learning and performance management software for corporations and higher education institutions, announced ...